Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Omalizumab Reduces Exacerbations of Moderate to Severe Persistent Allergic Asthma Independent of Former Smoking Status: Presented at ERS - (DGDispatch)
    Hay Fever May Be Best Treated With Self-Adjusted Dosing - (DGNews)
    Mometasone Furoate Nasal Spray Significantly Reduces Nasal Congestion Associated With Allergic Rhinitis: Presented at AAO-HNSF - (DGDispatch)
    FDA Approves Triamcinolone Acetonide for Allergic Rhinitis in Children Aged 2 to 5 years - (DGNews)
    Mometasone Furoate Effective Against Ocular Symptoms of Seasonal Allergic Rhinitis: Presented at AAO-HNSF - (DGDispatch)

    News archive

     Recent webcasts/CME - Allergy Other
    New Perspectives on Allergy Management: Ophthalmologists and Allergists Weigh in on Key Issues
    Food Allergies: When the Food Comes to Bite the Gut

    Webcasts/CME archive

     Recent cases - Allergy Other
      Allergic Enterocolitis and Protein-Losing Enteropathy as the Presentations of Manganese Leak From an Ingested Disk Battery: A Case Report
      Successful Desensitization with Human Insulin in a Patient with an Insulin Allergy and Hypersensitivity to Protamine: A Case Report
      Milk Allergy and Bottles Over the Back Fence: Two Single Patient Trials
      Patch Test Triggering Recurrence of Distant Dermatitis: The Flare-Up Phenomenon
      Pigeon Fanciers Lung: A Case Report

      Cases archive
        




      my personal edition > allergy other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Mometasone Furoate Useful For Children With Allergic Rhinitis: Presented at EAACI

      By Jill Stein

      PARIS, FRANCE -- June 11, 2003 -- Children with allergic rhinitis who are treated with once a day mometasone furoate nasal suspension (MFNS) respond well to the drug with no toxic effects.

      In a study of 56 children aged 2 to 5 years old who had allergic rhinitis and a positive skin test to pollen or other allergens, researchers observed no effects on the hypothalamic-pituitary-adrenal (HPA) axis and.

      These results were reported here on June 8th at the 22nd Congress of the European Academy of Allergology and Clinical Immunology.

      Jerry M. Herron, MD, Arkansas Research Medical Testing Center, in Little Rock, Arkansas, led a team of researchers in evaluating the systemic safety of MFNS 100 mcg once each morning at a dose of 50 mcg per spray per nostril for 42 consecutive days, compared with placebo, by measuring HPA axis function.

      The study excluded children who had used oral corticosteroids, orally inhaled corticosteroids, or intranasal corticosteroids within the prior 6 months, or intramuscular corticosteroids within the prior year.

      Treatments were administered at the study site under the supervision of a blinded third-party administrator to assure compliance. Fifty-two patients completed all 42 days of treatment.

      No significant differences were observed between MFNS and placebo treatment in measurements of serum cortisol (measured as the area under the concentration versus time curve [AUC] 0-24) or urinary-free cortisol (corrected for creatinine) at baseline and on day 42. Only one of the plasma samples had a detectable level of mometasone furoate.

      Follow-up physical examinations and vital signs for all patients were within normal ranges. No patient showed any clinically relevant changes in electrocardiogram or laboratory tests, and no patient discontinued treatment due to adverse events.

      The most common adverse events were mild to moderate headache and rhinorrhoea, which were reported in both the treatment and placebo groups.


      [Study title: Systemic Safety Of Once-Daily Treatment With Mometasone Furoate Nasal Spray (MFNS) 100 mcg In Patients Ages 2 to 5 Years Old With Allergic Rhinitis (AR). Abstract 586]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send